Olimab Denosumab 60 Injection

About Olimab Denosumab 60 Injection

Olimab Denosumab 60 mg Injection is a monoclonal antibody used for the treatment of osteoporosis and bone-related disorders. It works by inhibiting RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a protein responsible for bone resorption, thereby strengthening bones and reducing the risk of fractures.

This injection is widely prescribed for postmenopausal women with osteoporosis, men at high risk of fractures, and patients experiencing bone loss due to cancer therapies.

• Treatment of osteoporosis in postmenopausal women

• Osteoporosis in men at high fracture risk

• Bone loss associated with hormone-deprivation therapy

• Prevention of fractures

• Management of bone density loss

• Increases bone mass and strength

• Reduces risk of vertebral and non-vertebral fractures

• Long-acting therapy with dosing once every 6 months

• Proven efficacy in osteoporosis management

• Recommended dose: 60 mg once every 6 months

• Administered via subcutaneous injection

• To be given under medical supervision

• Store at 2C to 8C (Refrigerated)

• Do not freeze

• Protect from light

• Prescription-only medicine

• Not recommended during pregnancy or breastfeeding without medical advice

• Calcium and vitamin D supplementation may be advised